<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390102</url>
  </required_header>
  <id_info>
    <org_study_id>EPICURE</org_study_id>
    <secondary_id>CER-20809</secondary_id>
    <nct_id>NCT02390102</nct_id>
  </id_info>
  <brief_title>Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement</brief_title>
  <acronym>EPICURE</acronym>
  <official_title>Combined ErythroPoietin and Iron Therapy for AnemiC Patients With Severe Symptomatic Aortic Stenosis Undergoing Transcatheter Aortic Valve REplacement- The EPICURE Trial A Prospective Double Blind Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy of Erythropoietin (EPO) (+ iron) in
      reducing the rate of red blood cell transfusion requirements in patients with aortic stenosis
      undergoing transcatheter aortic valve replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN

      Prospective randomized double blind study including patients diagnosed with severe
      symptomatic aortic stenosis and anemia undergoing aortic valve replacement. The patients will
      be identified in the cardiac surgery / aortic stenosis outpatient clinic or in the
      hospitalization department of the Institut Universitaire de Cardiologie et de Pneumologie de
      Quebec.

      SAMPLE SIZE

      100 patients (50 patients per group).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of red blood cell transfusion</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of packets of red cells</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin value</measure>
    <time_frame>One day before index procedure</time_frame>
    <description>Analysis g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin value</measure>
    <time_frame>For the duration of hospital stay, an expected average of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak of troponin and creatinine kinase</measure>
    <time_frame>For the duration of hospital stay, an expected average of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute kidney injury</measure>
    <time_frame>At 48 hours following procedure</time_frame>
    <description>Acute kidney injury defined as &gt;25% decrease of estimated glomerular filtration rate (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of hemodialysis</measure>
    <time_frame>For the duration of hospital stay, an expected average of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of new onset atrial fibrillation</measure>
    <time_frame>For the duration of hospital stay, an expected average of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hospital stay</measure>
    <time_frame>For the duration of hospital stay, an expected average of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of intensive unit care stay</measure>
    <time_frame>For the duration of hospital stay, an expected average of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>At 30-day, 1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At 30-day, 6-month, 1-year</time_frame>
    <description>Questionnaire, Visual scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis of Erythropoietin-therapy</measure>
    <time_frame>For the duration of hospital stay, an expected average of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke rate</measure>
    <time_frame>At 30-day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anemia</condition>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Erythropoietin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose: darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose Administered at days 10 (±4) and 1 (±1) before the index procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage: Saline solution 0.9% Administered at days 10 (±4) and 1 (±1) before the index procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose</description>
    <arm_group_label>Erythropoietin</arm_group_label>
    <other_name>Darboepoetin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution 0.9%</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥60-year old

          2. Symptomatic aortic stenosis with a clinical indication for transcatheter aortic valve
             replacement, regardless of simultaneous percutaneous coronary intervention

          3. Anemia defined according to the World Health Organization (WHO) definition 69:

               1. Men: Hemoglobin&lt;130 g/L

               2. Women: &lt;120 g/L

        Exclusion Criteria:

          1. Contraindication for transcatheter aortic valve replacement.

          2. Erythropoietin treatment within last 30 days before Aortic Valve Replacement

          3. Known anemia due to aplasia, other hemoglobinopathy or active bleeding requiring blood
             transfusion within last 30 days before Aortic Valve Replacement

          4. Ferritin&gt;800 µg/L

          5. Uncontrolled hypertension (Blood pressure&gt;175/95 )

          6. Platelet count&gt;450,000/L

          7. Recent myocardial infarction requiring percutaneous coronary intervention or disabling
             stroke (within the last 30 days)

          8. Dialysis patients

          9. Hemodynamic instability as defined as the need of hemodynamic support with inotropic
             drugs, intraortic balloon pump counter-pulsation or left ventricular assist device
             before index procedure

         10. Active cancer or very high risk of thromboembolic events

         11. Known allergy or hypersensitivity to intravenous iron or Erythropoietin therapy

         12. No written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Rodes Cabau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Universitaire de Cardiologie et de Pneumologie de Quebec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Cote, MSc</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>2646</phone_ext>
      <email>melanie.cote@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Marina Urena, MD</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3484</phone_ext>
      <email>marinaua@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Josep Rodes Cabau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Karkouti K, Wijeysundera DN, Beattie WS; Reducing Bleeding in Cardiac Surgery (RBC) Investigators. Risk associated with preoperative anemia in cardiac surgery: a multicenter cohort study. Circulation. 2008 Jan 29;117(4):478-84. doi: 10.1161/CIRCULATIONAHA.107.718353. Epub 2008 Jan 2.</citation>
    <PMID>18172032</PMID>
  </reference>
  <reference>
    <citation>Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, Snyder-Ramos SA, Moehnle P, Mangano DT; Investigators of the Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation. 2007 Jul 31;116(5):471-9. Epub 2007 Jul 9.</citation>
    <PMID>17620512</PMID>
  </reference>
  <reference>
    <citation>Karkouti K, Djaiani G, Borger MA, Beattie WS, Fedorko L, Wijeysundera D, Ivanov J, Karski J. Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery. Ann Thorac Surg. 2005 Oct;80(4):1381-7.</citation>
    <PMID>16181875</PMID>
  </reference>
  <reference>
    <citation>Van Mieghem NM, Nuis RJ, Tzikas A, Piazza N, Schultz C, Serruys PW, de Jaegere PP. Prevalence and prognostic implications of baseline anaemia in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2011 Jun;7(2):184-91. doi: 10.4244/EIJV7I2A32.</citation>
    <PMID>21646060</PMID>
  </reference>
  <reference>
    <citation>van Straten AH, Hamad MA, van Zundert AJ, Martens EJ, Schönberger JP, de Wolf AM. Preoperative hemoglobin level as a predictor of survival after coronary artery bypass grafting: a comparison with the matched general population. Circulation. 2009 Jul 14;120(2):118-25. doi: 10.1161/CIRCULATIONAHA.109.854216. Epub 2009 Jun 29.</citation>
    <PMID>19564556</PMID>
  </reference>
  <reference>
    <citation>Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J; International Consortium for Evidence Based Perfusion, Baker RA, Dickinson TA, FitzGerald DJ, Likosky DS, Shann KG. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011 Mar;91(3):944-82. doi: 10.1016/j.athoracsur.2010.11.078. Review.</citation>
    <PMID>21353044</PMID>
  </reference>
  <reference>
    <citation>Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007 Nov 27;116(22):2544-52. Epub 2007 Nov 12.</citation>
    <PMID>17998460</PMID>
  </reference>
  <reference>
    <citation>Bucerius J, Gummert JF, Borger MA, Walther T, Doll N, Onnasch JF, Metz S, Falk V, Mohr FW. Stroke after cardiac surgery: a risk factor analysis of 16,184 consecutive adult patients. Ann Thorac Surg. 2003 Feb;75(2):472-8.</citation>
    <PMID>12607656</PMID>
  </reference>
  <reference>
    <citation>Paone G, Brewer R, Theurer PF, Bell GF, Cogan CM, Prager RL; Michigan Society of Thoracic and Cardiovascular Surgeons. Preoperative predicted risk does not fully explain the association between red blood cell transfusion and mortality in coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2012 Jan;143(1):178-85. doi: 10.1016/j.jtcvs.2011.09.015. Epub 2011 Oct 19.</citation>
    <PMID>22014719</PMID>
  </reference>
  <reference>
    <citation>Koch CG, Li L, Van Wagoner DR, Duncan AI, Gillinov AM, Blackstone EH. Red cell transfusion is associated with an increased risk for postoperative atrial fibrillation. Ann Thorac Surg. 2006 Nov;82(5):1747-56.</citation>
    <PMID>17062241</PMID>
  </reference>
  <reference>
    <citation>Surgenor SD, DeFoe GR, Fillinger MP, Likosky DS, Groom RC, Clark C, Helm RE, Kramer RS, Leavitt BJ, Klemperer JD, Krumholz CF, Westbrook BM, Galatis DJ, Frumiento C, Ross CS, Olmstead EM, O'Connor GT. Intraoperative red blood cell transfusion during coronary artery bypass graft surgery increases the risk of postoperative low-output heart failure. Circulation. 2006 Jul 4;114(1 Suppl):I43-8.</citation>
    <PMID>16820613</PMID>
  </reference>
  <reference>
    <citation>Bagur R, Webb JG, Nietlispach F, Dumont E, De Larochellière R, Doyle D, Masson JB, Gutiérrez MJ, Clavel MA, Bertrand OF, Pibarot P, Rodés-Cabau J. Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. Eur Heart J. 2010 Apr;31(7):865-74. doi: 10.1093/eurheartj/ehp552. Epub 2009 Dec 27.</citation>
    <PMID>20037180</PMID>
  </reference>
  <reference>
    <citation>Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology. 2011 Nov;115(5):929-37. doi: 10.1097/ALN.0b013e318232004b.</citation>
    <PMID>22027622</PMID>
  </reference>
  <reference>
    <citation>Kiyama H, Ohshima N, Imazeki T, Yamada T. Autologous blood donation with recombinant human erythropoietin in anemic patients. Ann Thorac Surg. 1999 Nov;68(5):1652-6.</citation>
    <PMID>10585037</PMID>
  </reference>
  <reference>
    <citation>Sowade O, Warnke H, Scigalla P, Sowade B, Franke W, Messinger D, Gross J. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood. 1997 Jan 15;89(2):411-8.</citation>
    <PMID>9002942</PMID>
  </reference>
  <reference>
    <citation>Gombotz H. Subcutaneous epoetin alfa as an adjunct to autologous blood donation before elective coronary artery bypass graft surgery. Semin Hematol. 1996 Apr;33(2 Suppl 2):69-70; discussion 71-2.</citation>
    <PMID>8723587</PMID>
  </reference>
  <reference>
    <citation>Weltert L, D'Alessandro S, Nardella S, Girola F, Bellisario A, Maselli D, De Paulis R. Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: a randomized blind controlled study. J Thorac Cardiovasc Surg. 2010 Mar;139(3):621-6; discussion 626-7. doi: 10.1016/j.jtcvs.2009.10.012. Epub 2009 Dec 29.</citation>
    <PMID>20042202</PMID>
  </reference>
  <reference>
    <citation>Yazicioğlu L, Eryilmaz S, Sirlak M, Inan MB, Aral A, Taşöz R, Eren NT, Kaya B, Akalin H. Recombinant human erythropoietin administration in cardiac surgery. J Thorac Cardiovasc Surg. 2001 Oct;122(4):741-5.</citation>
    <PMID>11581607</PMID>
  </reference>
  <reference>
    <citation>Kyo S, Omoto R, Hirashima K, Eguchi S, Fujita T. Effect of human recombinant erythropoietin on reduction of homologous blood transfusion in open-heart surgery. A Japanese Multicenter study. Circulation. 1992 Nov;86(5 Suppl):II413-8.</citation>
    <PMID>1424032</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Josep Rodes-Cabau</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Severe aortic stenosis</keyword>
  <keyword>Red blood cell transfusion</keyword>
  <keyword>Erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

